Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly defined high-risk patients who continue to do badly. Novel therapeutic approa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood cancer journal (New York) 2017-03, Vol.7 (3), p.e549-e549
Hauptverfasser:	Pawlyn, C, Bright, M D, Buros, A F, Stein, C K, Walters, Z, Aronson, L I, Mirabella, F, Jones, J R, Kaiser, M F, Walker, B A, Jackson, G H, Clarke, P A, Bergsagel, P L, Workman, P, Chesi, M, Morgan, G J, Davies, F E
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/2489/68 631/80/82/23 692/4028/67/1990/804 692/700/1750 Apoptosis - genetics Biomarkers Biomedical and Life Sciences Biomedicine Cancer Research Cell Cycle Checkpoints - genetics Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - genetics Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors Enhancer of Zeste Homolog 2 Protein - genetics Epigenesis, Genetic Gene Expression Gene Expression Profiling Hematology Histones - metabolism Humans Kaplan-Meier Estimate Mesenchymal Stem Cells - metabolism Multiple Myeloma - diagnosis Multiple Myeloma - genetics Multiple Myeloma - mortality Multiple Myeloma - therapy Oncology Original original-article Phenotype Prognosis Proportional Hazards Models RNA, Messenger - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!